February 28, 2017
FDA OK’s AstraZeneca’s diabetes drug
US Food and Drug Administration (FDA) has approved AstraZeneca’s once-daily Qtern (10mg dapagliflozin and 5mg saxagliptin) for the treatment of type-2 diabetes.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: AstraZeneca
February 23, 2017
China updates key drug list in boost for Big Pharma
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
February 20, 2017
TerSera buys commercial rights for AstraZeneca’s cancer drug in North America
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
February 17, 2017
AstraZeneca’s breast cancer drug trial shows positive results
AstraZeneca has announced positive results from its Phase III OLYMPIAD trial comparing Lynparza (olaparib) tablets (300mg twice daily) to physician’s choice of a standard of care chemotherapy in the treatment of patients with HER2-negative metastatic breast cancer harbouring germline BRCA1 or BRCA2 mutations.
February 9, 2017
Pulmonary drug delivery devices market to reach $43.05 billion by 2024
The Global Pulmonary Drug Delivery Devices Market demonstrates a high degree of competition between GlaxoSmithKline Plc, Boehringer Ingelheim GmbH, AstraZeneca Plc, Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
February 2, 2017
AstraZeneca’s sales drop, expects to launch several new drugs this year
AstraZeneca’s hopes to launch several cancer, respiratory and metabolic diseases drugs, as it expects to see the effects of its long-term growth. The drugmaker nears the end of its patent-expiry period as it expects to bring new medicines to the stores is.
January 26, 2017
AstraZeneca’s Symbicort for asthma available for 6-12 y.o. children in USA, FDA issues exclusivity rights
AstraZeneca’s Symbicort Inhalation Aerosol is going to be available for 6-12 years old children with asthma in the US
January 17, 2017
AstraZeneca tests overall and progression-free survivals in cancer related trials, focused on China
AstraZeneca has provided updates on some of its cancer related clinical trials including 1st-line non-small cell lung cancer (NSCLC). and a…
January 10, 2017
IT provider for healthcare market Instem names new COO
An IT provider for healthcare market Instem, has appointed MaryBeth Thompson as Chief Operating Officer of the Group. Thompson has not been appointed to the company’s main Board, and she will report to Phil Reason, CEO.
December 23, 2016
AstraZeneca, Pfizer complete more than a billion dollars worth antibiotics sale agreement
AstraZeneca has sold to Pfizer the commercialization and development rights of its late-stage small molecule antibiotics business, comprising the approved antibiotics Merrem, Zinforo and Zavicefta, and ATM-AVI and CXL, which are in clinical development.